{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:21:50Z","timestamp":1787170910620,"version":"build-2736575974"},"reference-count":28,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2021,5,2]],"date-time":"2021-05-02T00:00:00Z","timestamp":1619913600000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Res &amp; Perspec"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>To evaluate the clinical benefit of new medicines for type 2 diabetes mellitus (T2DM), the Dutch guideline committee T2DM in primary care established the importance of outcomes and minimal clinically important differences (MCIDs). The present study used an online questionnaire to investigate healthcare professionals\u2019 opinions about the importance of outcomes and preferences for MCIDs. A total of 211 physicians, pharmacists, practice nurses, diabetes nurses, nurse practitioners and physician assistants evaluated the importance of mortality, macro\u2010 and microvascular morbidity, HbA1c, body weight, quality of life, (overall) hospital admissions and severe and other hypoglycemia on a 9\u2010point scale. All outcomes were considered critical (mean scores 7\u20139), except for body weight and other hypoglycemia (mean scores 4\u20136). Only HbA1c and hospital admissions were valued differently by the guideline committee (not critical). Other relevant outcomes according to the respondents were adverse events, ease of use and costs. Median MCIDs were 4\u00a0mmol\/mol for HbA1c (guideline: 5\u00a0mmol\/mol) and 3\u00a0kg for body weight (guideline: 5\u00a0kg weight gain and 2,5\u00a0kg weight loss). Healthcare professionals preferred relative risk reductions of 20% for mortality (guideline: 10%) and macrovascular morbidity (guideline: 25%) and 50% for other hypoglycaemia (guideline: 25%). The MCID of 25% for microvascular morbidity, hospital admissions and severe hypoglycaemia corresponded to the guideline\u2010MCID. Healthcare professionals\u2019 preferences were thus comparable to the views of the guideline committee. However, healthcare professionals had a stricter view on the importance of HbA1c and hospital admissions and the MCIDs for mortality and other hypoglycemia.<\/jats:p>","DOI":"10.1002\/prp2.750","type":"journal-article","created":{"date-parts":[[2021,5,2]],"date-time":"2021-05-02T13:24:46Z","timestamp":1619961886000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Alignment between outcomes and minimal clinically important differences in the Dutch type 2 diabetes mellitus guideline and healthcare professionals\u2019 preferences"],"prefix":"10.1002","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0971-8388","authenticated-orcid":false,"given":"Marloes","family":"Dankers","sequence":"first","affiliation":[{"name":"Dutch Institute for Rational Use of Medicine Utrecht the Netherlands"},{"name":"Department of PharmacoTherapy, \u2010Epidemiology and \u2010Economics (PTEE Groningen Research Institute of Pharmacy Faculty of Science and Engineering University of Groningen Groningen the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjorie H. J. M. G.","family":"Nelissen\u2010Vrancken","sequence":"additional","affiliation":[{"name":"Dutch Institute for Rational Use of Medicine Utrecht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertien H.","family":"Hart","sequence":"additional","affiliation":[{"name":"Department of General Practice Julius Center for Health Sciences and Primary Care University Medical Center Utrecht Utrecht University Utrecht the Netherlands"},{"name":"Leidsche Rijn Julius Healthcare Centers Utrecht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke C.","family":"Lambooij","sequence":"additional","affiliation":[{"name":"Dutch Institute for Rational Use of Medicine Utrecht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liset","family":"van Dijk","sequence":"additional","affiliation":[{"name":"Department of PharmacoTherapy, \u2010Epidemiology and \u2010Economics (PTEE Groningen Research Institute of Pharmacy Faculty of Science and Engineering University of Groningen Groningen the Netherlands"},{"name":"Nivel, Netherlands Institute for Health Services Research Utrecht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aukje K.","family":"Mantel\u2010Teeuwisse","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Clinical Pharmacology Utrecht Institute for Pharmaceutical Sciences (UIPS Utrecht University Utrecht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,5,2]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz486"},{"key":"e_1_2_10_3_1","volume-title":"NHG\u2010Standaard diabetes mellitus type","author":"Nederland Huisartsen Genootschap (NHG)","year":"2018"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.09.012"},{"key":"e_1_2_10_5_1","volume-title":"Totstandkoming en methoden NHG\u2010Standaard Diabetes mellitus type 2 (M01)","author":"Nederland Huisartsen Genootschap (NHG)","year":"2018"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/biom.12251"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.4310"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2016.04.009"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1900\/RDS.2008.5.128"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr437"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.0029"},{"key":"e_1_2_10_12_1","volume-title":"Type 2 diabetes in adults: management Clinical Guideline. [NG28]","author":"National Institute for Health and Care Excellence (NICE)","year":"2015"},{"key":"e_1_2_10_13_1","volume-title":"Diabetes mellitus type 2 in de tweede lijn","author":"Nederlandse Internisten Vereniging (NIV)","year":"2018"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2011.01.012"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.625404"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2009.02696.x"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/1715163513506547"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12566"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.4081\/jphr.2014.311"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281998"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/0145721706288182"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2013.06.001"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12091"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/edn.143"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2004.052233"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01519"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/ptj\/81.8.1464"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.2002.11111.x"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7417.694"}],"container-title":["Pharmacology Research &amp; Perspectives"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.750","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/prp2.750","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.750","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T02:44:49Z","timestamp":1693190689000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/prp2.750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1002\/prp2.750"],"URL":"https:\/\/doi.org\/10.1002\/prp2.750","archive":["Portico"],"relation":{},"ISSN":["2052-1707","2052-1707"],"issn-type":[{"value":"2052-1707","type":"print"},{"value":"2052-1707","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"2021-01-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00750"}}